Birthing positions in women receiving epidural analgesia

Introduction

The aim of the HTA programme is to ensure that high quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage, provide care in or develop policy for the NHS. Topics for research are identified and prioritised to meet the needs of the NHS. Health technology assessment forms a substantial portfolio of work within the National Institute for Health Research and each year about fifty new studies are commissioned to help answer questions of direct importance to the NHS. The studies include both primary research and evidence synthesis.

Question

What is the clinical and cost effectiveness of an upright maternal position in second stage labour to reduce instrumental deliveries in women receiving epidural analgesia?

- 1 **Technology:** Upright maternal position (applicants to define and justify).
- **Patient group:** Women in the second stage of labour who have received epidural anaesthesia (applicants to define and justify types and doses of epidural analgesia which are eligible to be included), and in whom the intention is vaginal delivery.
- 3 Setting: Secondary care.
- 4 Control or comparator treatment: Supine delivery position.
- **Design:** A randomised controlled trial to compare upright and supine delivery positions (applicants to define and justify). Randomisation might be by individual, or cluster randomised.
- 6 Primary outcomes/quality of life: Non instrumental vaginal delivery. Secondary outcomes: Incidence of Caesarean section, post partum haemorrhage, vaginal/perineal trauma, urinary and faecal incontinence, other bowel and sexual problems, patient satisfaction, neonatal outcomes: APGAR scores at 1 and 5 minutes. Estimate of resource impact.
- 7 **Minimum duration of follow-up:** 1 year.

Background to commissioning brief:

The overall national rate of women in UK hospitals who have an epidural while giving birth is around 25-30%. However, the figure varies considerably from hospital to hospital. Epidural analgesia is associated with an increase in the risk of instrumental delivery, compared to other forms of analgesia for labour. There is controversy around whether being upright or lying down has advantages for women delivering their babies. Several physiological advantages have been claimed for non-recumbent or upright labour.

Research is required in the form of a randomised controlled trial to investigate the clinical and cost effectiveness of an upright maternal position in second stage labour to reduce instrumental deliveries in women with epidural analgesia.

Notes to Applicants

For many of the questions posed by the HTA programme, a randomised controlled trial is likely to be the most appropriate method of providing an answer. However, there may be practical or ethical reasons why this might not be possible. Applicants proposing other research methods are invited to justify these choices.

Applicants are asked to:

- 1. Follow the Medical Research Council's Good Clinical Practice guidelines (http://www.mrc.ac.uk/pdf-ctg.pdf) when planning how studies, particularly RCTs, will be supervised. Further advice specific to each topic will be given by the HTA programme at full proposal and contract stages.
- 2. Note that trials involving medicinal products must comply with "The Medicines for Human Use (Clinical Trials) Regulations 2004". In the case of such trials, the DH expects the employing institution of the chief investigator to be nominated as the sponsor. Other institutions may wish to take on this responsibility or agree co-sponsorship with the employing institution. The DH is prepared to accept the nomination of multiple sponsors. Applicants who are asked to submit a full proposal will need to obtain confirmation of a sponsor(s) to complete their application. The DH reserve the right to withdraw from funding the project if they are not satisfied with the arrangements put in place to conduct the trial.

The MHRA (<u>info@mhra.gsi.gov.uk</u>, <u>http://www.mhra.gov.uk</u>) can provide guidance as to whether your trial would be covered by the regulations. The DH/MRC website (<u>http://www.ct-toolkit.ac.uk/</u>) also contains the latest information about Clinical Trials regulations and a helpful FAQ page.

Research networks

The HTA programme expects, where appropriate, that applicants will work with the relevant research network.

Making an application

If you wish to submit an outline proposal on this topic, complete the electronic application form and return it to the HTA Commissioning Manager at the National Coordinating Centre for Health Technology Assessment, Mailpoint 728 Boldrewood, University of Southampton, Southampton SO16 7PX by 23 April 2008. Outline applications will be considered by the HTA Commissioning Board at its meeting in July 2008. If they are acceptable, investigators will be given a minimum of eight weeks to submit a full proposal.

Applications received after 1300 hours on the due date will not be considered.

Please see GUIDANCE ON APPLICATIONS overleaf.

Guidance on applications

Required expertise

HTA is a multidisciplinary enterprise. It needs to draw on the expertise and knowledge of clinicians and of those trained in health service research methodologies such as health economics, medical statistics, study design and qualitative approaches. The HTA programme expects teams proposing randomised controlled trials to include input from an accredited clinical trials unit, or one with equivalent experience. Applicants are also expected to engage a qualified Trial Manager for appropriate projects. A commitment to team working must be shown and applicants may wish to consider a collaborative approach between several institutions.

Public involvement in research

The HTA programme recognises the increasing active involvement of members of the public in research and would like to support research projects appropriately. The HTA programme encourages applicants to consider *how* the scientific quality, feasibility or practicality of their proposal *might* be improved by involving members of the public. Research teams wishing to involve members of the public should include in their application: the aims of active involvement in this project; a description of the members of the public (to be) involved; a description of the methods of involvement; and an appropriate budget. Applications that involve members of the public will not, for that reason alone, be favoured over proposals that do not but it is hoped that the involvement of members of the public will improve the quality of the application.

Outcomes

Wherever possible, the results of HTA should provide information about the effectiveness and costeffectiveness of care provided in its usual clinical setting and for the diverse subjects who would be
eligible for the interventions under study. The endpoints of interest will in most cases include disease
specific measures, health related quality of life and costs (directly and indirectly related to patient
management). Wherever possible, these measurements should be made by individuals who are
unaware of the treatment allocation of the subjects they are assessing. We encourage applicants to
involve users of health care in the preparation of their proposal, for instance in selecting patientoriented outcomes. A period of follow up should be undertaken which is sufficient to ensure that a
wider range of effects are identified other than those which are evident immediately after treatment.
These factors should guide applicants in their choice of subjects, settings and measurements made.

Sample size

A formal estimate should be made of the number of subjects required to show important differences in the chosen primary outcome measure. Justification of this estimate will be expected in the application.

Communication

Communication of the results of research to decision makers in the NHS is central to the HTA Programme. Successful applicants will be required to submit a single final report for publication by the HTA programme. They are also required to seek peer-reviewed publication of their results elsewhere and may also be asked to support the NCCHTA in further efforts to ensure that results are readily available to all relevant parties in the NHS. Where findings demonstrate continuing uncertainty, these should be highlighted as areas for further research.

Timescale

There are no fixed limits on the duration of projects or funding and proposals should be tailored to fully address the problem (including long-term follow-up if necessary). Applicants should consider however that there is a pressing need within the NHS for this research, and so the duration of the research needs to be timely.